Bengaluru, June 27 -- This small-cap Pharma Stock, engaged in manufacturing and marketing pharmaceutical formulations and APIs, serving regulated and emerging markets with a focus on quality, compliance, and innovation, is in focus after management expected 50% growth in revenue and 100% growth in net profit for FY26.

With a market capitalization of Rs. 2,609.86 crore, the shares of Senores Pharmaceuticals Limited closed at Rs. 566.70 per equity share, down nearly 1.26 percent from its previous day's close price of Rs. 573.95.

Guidance: For FY26, Senores Pharmaceuticals has guided for strong growth, targeting at least 50 percent year-on-year revenue growth and aiming for 100 percent growth in profit after tax (PAT) compared to current ...